Special Issue Editors
Dr. Şerife Mehlika Kuşkonmaz
Ankara Training and Research Hospital, Department of Endocrinology and Metabolism
Email: mehlikaisildak@gmail.com
Diabetes treatment and side effects of antidiabetic medications, disorders of parathyroid, pituitary diseases.
Dr. Şerife Mehlika Kuşkonmaz was born in 1975 in Ankara. She was graduated from Hacettepe University Faculty of Medicine at 1999. She trained in Internal Medicine and in Endocrinology and Metabolism at Hacettepe University Hospital between 2000-2008. She worked in different medical centers as a specialist in the field of endocrinology, including Başkent University Hospital and Güven Hospital. Dr. Kuşkonmaz is now working as an associate professor in Ankara Research and Training Hospital Department of Endocrinology and Metabolism.
Dr. Hiroshi Bando, MD, Ph.D., FACP
Tokushima University / Medical Research, Nakashowa 1-61, Tokushima City 770-0943, Japan
Email: pianomed@bronze.ocn.ne.jp
Diabetes, Metabolic Syndrome, Primary Care Medicine, Complementary and Alternative Medicine (CAM), Integrative Medicine (IM), Music Therapy (MT), Sports Medicine.
Dr. Bando had graduated from Tokushima University, School of Medicine in 1981. After obtaining the ECFMG certificate, he participated in the family practice residency training in the United States. He got the degree of Doctors of Medicine in 1989 and engaged in the research of endocrine and metabolic medicine at Tokushima University. He has been a board member and specialist in several medical societies, such as diabetes, primary care, anti-aging medicine, integrative medicine (IM), music therapy and sports medicine. He was the chairperson of the 8th annual conference of Japanese Primary Care Association (JPCA) in 2017 with 4,500 attendees.
Important Discussions on SGLT2 Inhibitor
This special series of reviews focuses on the newest class of SGLT2 inhibitors.
Sodium-glucose transporter 2 (SGLT2) inhibitors are also called Gliflozins. These prevent the reabsorption of glucose from the blood that’s filtered through your kidneys, therefore facilitating glucose excretion in the urine. This helps reduce your blood sugar levels.
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors are also called Gliflozins. These prevent the reabsorption of glucose from the blood that’s filtered through your kidneys, therefore facilitating glucose excretion in the urine. This helps reduce your blood sugar levels.
To date, the U.S. Food and Drug Administration (FDA) has approved four types of SGLT2 inhibitors to treat type 2 diabetes:
Canagliflozin (Invokana)
Dapagliflozin (Farxiga)
Empagliflozin (Jardiance)
Ertugliflozin (Steglatro)
Important Keywords
- SGLT2 (Sodium Glucose Transporter 2) Inhibitors
- Gliflozins
- Blood Sugar
- Diabetes Mellitus
- Type II Diabetes
- Kidneys
- Glucose in Blood
- Body Weight
- Blood Pressure
- Dual Therapy
- Diabetic Ketoacidosis
- Insulin
- Diuretic Effects
- Antidiabetics
- Hypoglycemia